TPX2 and hepatocellular carcinoma: In MHCC97-L and HepG2 cells, overexpression of TPX2 caused the acceleration of the sorafenib metabolism or clearance (Fig. 5A, E), and the half-life (t1/2) value of sorafenib in HCC cells decreased (Table 7).